Aurobindo Pharma receives final approvals for Quetiapine Fumarate Tablets

28th March 2012

Aurobindo Pharma Limited is pleased to announce that the company has received final approvals from the US Food & Drug Administration (USFDA) to market Quetiapine Fumarate Tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg (ANDA 091388)

Quetiapine Fumarate Tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg are the generic equivalent of AstraZeneca LP's Seroquel® Tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg. Quetiapine Fumarate Tablets are indicated for the treatment of serious psychotic disorders such as Schizophrenia and Bipolar Disorder and falls under the Neurological (CNS) therapeutic category.

The product has been approved out of Unit III facility in Hyderabad, India

Aurobindo now has a total of 147 ANDA approvals (118 Final approvals and 29 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com